Nasdaq
$0.5906▲ 0.72%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $50.5MShares out 85.5M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
4- 9.4After-hours26.09.05 05:318-KKey event#●●●#●●●#●●●
Rein Therapeutics, Inc.
Rein Therapeutics has released an updated presentation regarding its LTI-03 product candidate for the treatment of Idiopathic Pulmonary Fibrosis (IPF). The company is currently enrolling patients for its Phase 2 RENEW clinical trial and highlighted the potential alveolar regenerative and anti-fibrotic properties of the drug.…more
$0.5906+0.72%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.27After-hours26.08.28 05:058-KKey event
Rein Therapeutics, Inc.
Rein Therapeutics has received a notice from Nasdaq stating that it is non-compliant with the minimum bid price requirement as its common stock closed below $1.00 for 30 consecutive trading days. The company has until February 17, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least 10 consecutive business days, or face delisting procedures.…more
$0.5906+0.72%vs prev closeView filingShare - 8.17Pre-market26.08.15 10:32filedSCHEDULE 13GOwnership
Rein Therapeutics, Inc.
Adar1 Capital Management, LLC and Daniel Schneeberger entered into a joint filing agreement on August 14, 2026, regarding the Schedule 13G filing for Rein Therapeutics, Inc. common stock. This agreement formalizes the joint reporting and management of their equity holdings in the company.…more
$0.5906+0.72%vs prev closeView filingShare
3 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 9.4Pre-market26.09.04 21:02#●●●#●●●
Rein Therapeutics to Present LTI-03 Clinical Data at ERS 2026 Congress
Rein Therapeutics announced it will present late-breaking clinical data for its idiopathic pulmonary fibrosis candidate, LTI-03, at the ERS 2026 Congress. This presentation serves as a progress update on their pipeline rather than a definitive clinical milestone.…more
$0.5906+0.72%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 9.4Pre-market26.09.04 21:00
●●●●●●●● ●●●●● ●●●●●●
Rein Therapeutics will present late-breaking clinical data for its idiopathic pulmonary fibrosis candidate, LTI-03, at the European Respiratory Society Congress. The presentation highlights the drug's potential in lung tissue repair and fibrosis inhibition as part of its ongoing Phase 2 trial.…more
$0.5906+0.72%vs prev close - 9.3After-hours26.09.04 05:01
●●●●●●●● ●●●●● ●●●●●●
Rein Therapeutics announced that its CEO will present at the Cantor Global Healthcare Conference and the H.C. Wainwright Global Investment Conference in September. This is a routine investor relations activity and does not provide immediate material impact on the stock price.…more
$0.5906+0.72%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report